Загрузка...
Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy
Paclitaxel has been shown to have clinical activity in the treatment of small cell lung cancer (SCLC). However, its role as third-line chemotherapy for SCLC after both etoposide- and camptothecin-based regimens has not been clarified. All patients with refractory SCLC who were treated with paclitaxe...
Сохранить в:
| Опубликовано в: : | Medicine (Baltimore) |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Wolters Kluwer Health
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5662365/ https://ncbi.nlm.nih.gov/pubmed/29049199 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000008176 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|